Literature DB >> 7480729

Ovarian cancer: staging with CT and MR imaging.

R Forstner1, H Hricak, K A Occhipinti, C B Powell, S D Frankel, J L Stern.   

Abstract

PURPOSE: To evaluate ovarian cancer staging and tumor resectability with computed tomography (CT) or magnetic resonance (MR) imaging.
MATERIALS AND METHODS: Eighty-two women underwent CT (n = 43) or MR imaging (n = 50); eleven of these 82 underwent both. Imaging was performed within 4 weeks of surgical staging. Radiologic, surgical, and histopathologic findings were compared.
RESULTS: Overall staging accuracy was similar for CT and MR imaging (77% [33 of 43] vs 78% [39 of 50]). Evaluation of pelvic cancer extent was better with MR imaging than with CT. There was no difference in detection of abdominal disease. Most mesenteric and small-bowel implants were not detected with either CT or MR imaging. For CT, the positive predictive value for cancer nonresectability was 100% (three of three patients); the negative predictive value was 92% (37 of 40 patients). The positive and negative predictive values for MR imaging were 91% (10 of 11 patients) and 97% (38 of 39 patients).
CONCLUSION: While the staging accuracy of both CT and MR imaging is only moderate, prediction of tumor resectability is excellent.

Entities:  

Mesh:

Year:  1995        PMID: 7480729     DOI: 10.1148/radiology.197.3.7480729

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  28 in total

1.  The value of abdominal CT scans in decision-making during chemotherapy in ovarian cancer.

Authors:  M A L van Lankveld; P H M Peeters; M A van Eijkeren; V C M Koot; P O Witteveen; W P Th M Mali
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 2.  ESUR guidelines: ovarian cancer staging and follow-up.

Authors:  Rosemarie Forstner; Evis Sala; Karen Kinkel; John A Spencer
Journal:  Eur Radiol       Date:  2010-09-14       Impact factor: 5.315

3.  Comparative evaluation of multidetector CT and MR imaging in the differentiation of adnexal masses.

Authors:  A C Tsili; C Tsampoulas; M Argyropoulou; I Navrozoglou; Y Alamanos; E Paraskevaidis; S C Efremidis
Journal:  Eur Radiol       Date:  2008-01-10       Impact factor: 5.315

Review 4.  Imaging spectrum of mesenteric masses.

Authors:  Radwan Diab; Mayur Virarkar; Mohammed Saleh; Sherif Elsheif; Sanaz Javadi; Priya Bhosale; Silvana Faria
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 5.  Mucinous Neoplasms of the Ovary: Radiologic-Pathologic Correlation.

Authors:  Jamie Marko; Kathryn I Marko; Suvidya L Pachigolla; Barbara A Crothers; Rubina Mattu; Darcy J Wolfman
Journal:  Radiographics       Date:  2019 Jul-Aug       Impact factor: 5.333

6.  An investigation of CNN models for differentiating malignant from benign lesions using small pathologically proven datasets.

Authors:  Shu Zhang; Fangfang Han; Zhengrong Liang; Jiaxing Tan; Weiguo Cao; Yongfeng Gao; Marc Pomeroy; Kenneth Ng; Wei Hou
Journal:  Comput Med Imaging Graph       Date:  2019-08-11       Impact factor: 4.790

7.  Multimodality imaging of ovarian cystic lesions: Review with an imaging based algorithmic approach.

Authors:  Ashish P Wasnik; Christine O Menias; Joel F Platt; Usha R Lalchandani; Deepak G Bedi; Khaled M Elsayes
Journal:  World J Radiol       Date:  2013-03-28

8.  Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Kaji; Ichio Fukasawa; Noriyuki Inaba; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

Review 9.  MR imaging in ovarian cancer.

Authors:  S A A Sohaib; R H Reznek
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

10.  Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial.

Authors:  G Ferrandina; G Sallustio; A Fagotti; G Vizzielli; A Paglia; E Cucci; A Margariti; L Aquilani; G Garganese; G Scambia
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.